Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.60 [0.48, 0.75] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
PFS (extension) | 0.71 [0.60, 0.84] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.52 [0.30, 0.91] | | < 1 | | 93% | 2 studies (2/-) | 98.9 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.99 [1.75, 2.28] | | > 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) (extension) | 2.28 [1.74, 3.00] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | NaN [NaN, NaN] | | < 1 | | 0% | 1 study (1/-) | NaN | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.11 [0.05, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.82 [0.47, 1.43] | | < 1 | | 0% | 2 studies (2/-) | 76.2 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 2.31 [1.58, 3.38] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.62 [0.28, 1.39] | | < 1 | | 0% | 1 study (1/-) | 87.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.26 [0.96, 1.65] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.56 [0.16, 1.93] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 3.10 [2.12, 4.54] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 5.98 [0.30, 119.72] | | < 1 | | 0% | 1 study (1/-) | 12.4 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.07 [0.01, 0.57] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 1.49 [0.25, 8.96] | | < 1 | | 0% | 1 study (1/-) | 33.2 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.49 [0.18, 1.31] | | < 1 | | 0% | 1 study (1/-) | 92.2 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 16.13 [0.92, 281.80] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 4.53 [0.97, 21.10] | | < 1 | | 0% | 1 study (1/-) | 2.7 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 1.66 [0.92, 3.00] | | < 1 | | 0% | 1 study (1/-) | 4.5 % | NA | not evaluable | | non important | - |
Dysgeusia TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Dyspepsia TRAE (grade 3-4) | 0.49 [0.02, 14.79] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
Dysphonia TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.46 [0.21, 0.99] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 20.26 [1.18, 348.03] | | < 1 | | 0% | 1 study (1/-) | 2.0 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.20 [0.85, 1.68] | | < 1 | | 0% | 1 study (1/-) | 14.7 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 10.01 [0.55, 183.83] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 7.99 [0.42, 151.61] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 4.33 [1.88, 10.00] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 5.19 [2.67, 10.10] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.56 [0.16, 1.93] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.49 [0.09, 2.71] | | < 1 | | 0% | 1 study (1/-) | 79.1 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.03 [0.00, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.48 [0.76, 2.89] | | < 1 | | 0% | 1 study (1/-) | 12.7 % | NA | not evaluable | | non important | - |
Pancreatitis TRAE (grade 3-4) | 0.99 [0.14, 7.07] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Proteinuria TRAE (grade 3-4) | 1.84 [0.67, 5.02] | | < 1 | | 0% | 1 study (1/-) | 11.8 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.99 [0.06, 15.89] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 1.66 [0.39, 6.99] | | < 1 | | 0% | 1 study (1/-) | 24.6 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.33 [0.09, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.3 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.02 [0.00, 0.35] | | < 1 | | 0% | 1 study (1/-) | 99.6 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Uveitis TRAE (grade 3-4) | 0.99 [0.02, 50.04] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.33 [0.03, 3.17] | | < 1 | | 0% | 1 study (1/-) | 83.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 5.00 [0.58, 42.98] | | < 1 | | 0% | 1 study (1/-) | 7.2 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.14 [0.04, 0.46] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 2.03 [0.59, 6.96] | | < 1 | | 0% | 2 studies (2/-) | 13.0 % | some concern | not evaluable | moderate | non important | - |
Asthenia AE (grade 3-4) | 0.83 [0.37, 1.88] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.56 [0.16, 1.93] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
Blood creatinine increased AE (grade 3-4) | 0.66 [0.11, 3.96] | | < 1 | | 0% | 1 study (1/-) | 67.5 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.94 [0.18, 21.52] | | < 1 | | 12% | 2 studies (2/-) | 29.5 % | some concern | not evaluable | moderate | non important | - |
Cough AE (grade 3-4) | 0.49 [0.04, 5.47] | | < 1 | | 0% | 1 study (1/-) | 71.6 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 3.22 [1.45, 7.19] | | < 1 | | 0% | 2 studies (2/-) | 0.2 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea AE (grade 3-4) | 1.97 [1.31, 2.96] | | < 1 | | 0% | 2 studies (2/-) | 0.1 % | some concern | not evaluable | moderate | non important | - |
Dysgeusia AE (grade 3-4) | 1.29 [0.15, 11.06] | | < 1 | | 0% | 2 studies (2/-) | 40.9 % | some concern | not evaluable | moderate | non important | - |
Dyspepsia AE (grade 3-4) | 0.49 [0.02, 14.79] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
Dysphonia AE (grade 3-4) | 1.46 [0.11, 19.00] | | < 1 | | 0% | 2 studies (2/-) | 38.8 % | some concern | not evaluable | moderate | non important | - |
Dyspnoea AE (grade 3-4) | 1.39 [0.44, 4.43] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.62 [0.27, 1.44] | | < 1 | | 64% | 2 studies (2/-) | 86.5 % | some concern | not evaluable | moderate | non important | - |
Headache AE (grade 3-4) | 1.99 [0.36, 10.93] | | < 1 | | 0% | 1 study (1/-) | 21.5 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 1.39 [1.01, 1.90] | | < 1 | | 40% | 2 studies (2/-) | 2.1 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism AE (grade 3-4) | 10.01 [0.55, 183.83] | | < 1 | | 0% | 1 study (1/-) | 6.2 % | NA | not evaluable | | non important | - |
Hypothyroidism AE (grade 3-4) | 2.98 [0.32, 28.06] | | < 1 | | 20% | 2 studies (2/-) | 17.2 % | some concern | not evaluable | moderate | non important | - |
Increase AST AE (grade 3-4) | 3.12 [1.51, 6.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 4.86 [2.62, 9.01] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
Mucosal inflammation AE (grade 3-4) | 0.49 [0.15, 1.64] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 2.02 [0.47, 8.75] | | < 1 | | 50% | 2 studies (2/-) | 17.5 % | some concern | not evaluable | moderate | non important | - |
Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 1.23 [0.74, 2.02] | | < 1 | | 0% | 2 studies (2/-) | 21.2 % | some concern | not evaluable | moderate | non important | - |
Proteinuria AE (grade 3-4) | 2.45 [1.35, 4.44] | | < 1 | | 0% | 2 studies (2/-) | 0.2 % | some concern | not evaluable | moderate | non important | - |
Pruritus AE (grade 3-4) | 1.98 [0.07, 59.29] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.99 [0.02, 50.04] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 2.14 [0.18, 26.02] | | < 1 | | 68% | 2 studies (2/-) | 27.7 % | some concern | not evaluable | moderate | non important | - |
Stomatitis AE (grade 3-4) | 0.56 [0.23, 1.37] | | < 1 | | 12% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.02 [0.00, 0.31] | | < 1 | | 0% | 1 study (1/-) | 99.7 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.94 [0.11, 8.34] | | < 1 | | 70% | 2 studies (2/-) | 52.1 % | some concern | not evaluable | moderate | non important | - |
Weight decreased AE (grade 3-4) | 19.85 [4.76, 82.76] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |